SMC unable to recommend dexamethasone (Ozurdex ®) intravitreal implant due to absence of submission

Source: Scottish Medicines Consortium (SMC)
Area: Evidence > Drug Specific Reviews
The Scottish Medicines Consortium (SMC) is unable to recommend the use of dexamethasone (Ozurdex ®) 0.7mg intravitreal implant within NHS Scotland for the treatment of adult patients with inflammation of the posterior segment of the eye presenting as non-infectious uveitis, as the holder of the marketing authorisation has not made a submission.

Full Story →